Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASABackground. In Russia, more than 600,000 cases of cancer are diagnosed annually, with 18.9 % of cases diagnosed at stage IV. Chemotherapy is the primary treatment for patients with metastatic cancer. Cisplatin is a widely used chemotherapeutic agent; however, it exhibits significant nephrotoxicity, often leading to dose reduction or even complete discontinuation of treatment. Given this, preventing the development of cisplatin-induced acute kidney injury is crucial.The aim of the study was to investigate the nephroprotective properties of resveratrol in cisplatin-induced acute kidney injury.Materials and methods. The study was conducted at the Research Institute of Pharmacology of Living Systems, Belgorod National Research University, using 40 male Wistar laboratory rats weighing 250–300g. To simulate acute kidney injury, animals were administered cisplatin at a dose of 5 mg/kg intraperitoneally on days 1 and 8 of the experiment. For nephroprotection, resveratrol was administered orally daily at a dose of 4 mg/kg or 12 mg/kg for 2 weeks. Functional tests and laboratory studies were performed 14 days after the first cisplatin administration.Results. The use of resveratrol in cisplatin-induced acute kidney injury was accompanied by pronounced dose-dependent nephroprotective effects, manifested by a decrease in plasma creatinine and urea levels, an increase in glomerular filtration rate, normalization of fractional sodium excretion, and an improvement in renal parenchymal microcirculation.Conclusions. The results of the study demonstrate the potential of using resveratrol to prevent the development of cisplatin-induced acute kidney injury.